AHMEDABAD, India,
Sept. 13,
2024 /PRNewswire/ -- Zydus Lifesciences Ltd., a
global innovation driven healthcare company announced that its
wholly owned subsidiary, Zydus Lifesciences Global FZE has
entered into an exclusive licensing and supply agreement with Viwit
Pharmaceuticals (Viwit), an innovation driven
biopharmaceutical and healthcare company, for gadobutrol injection
(generic version of GADAVISTTM) and gadoterate meglumine
injection (generic version of DOTAREM®) for the US
market.
As per the terms of the agreement, Viwit will be responsible for
ANDA submission, manufacturing and supplying the generic versions
of GADAVISTTM and DOTAREM®, following the
receipt of requisite regulatory approval. Zydus will exclusively
market, distribute, and sell these products in the US market. Both
the products are Gadolinium based Magnetic Resonance Imaging (MRI)
contrast agents and will be the first set of contrast agent
products in Zydus' injectable portfolio for the US market.
The total addressable market opportunity for gadobutrol
injection is estimated at US$ 120
million, and for gadoterate meglumine injection at
US$ 117 million in the US market (as
per IQVIA MAT Jul - 2024).
About Zydus
Zydus Lifesciences Ltd. with an overarching purpose of
empowering people with freedom to live healthier and more fulfilled
lives, is an innovative, global lifesciences company that
discovers, develops, manufactures, and markets a broad range of
healthcare therapies. The group has a significant presence in
cancer related therapies and offers a wide range of solutions with
cytotoxic, supportive & targeted drugs. The group employs over
27,000 people worldwide, including 1,400 scientists engaged in R
& D, and is driven by its mission to unlock new possibilities
in lifesciences through quality healthcare solutions that impact
lives. The group aspires to transform lives through path-breaking
discoveries. For more details visit www.zyduslife.com
About Viwit Pharmaceuticals
Viwit is an innovation driven biopharmaceutical and healthcare
company with integrated research and development, production and
marketing systems. Viwit is committed to building a platform for
pharmaceutical innovation and commercialization, and establishing
an ecosystem that serves the healthcare needs of the general
public. Viwit started as Boranes producing company and has evolved
into a healthcare company offering API and Drug Product development
and manufacturing as well as CDMO services. Viwit has three
integrated product R&D centers, three cGMP US FDA inspected
production facilities. By continuously improving the level, depth
and scope of innovation, Viwit makes every effort to provide people
with better health products and services, and to fulfil Viwit
vision of "Innovation for a Better Life". For more details visit
www.viwit.com.
Logo:
https://mma.prnewswire.com/media/2248031/4342289/Zydus_Logo.jpg
View original
content:https://www.prnewswire.com/news-releases/zydus-announces-exclusive-licensing-and-supply-agreement-for-two-gadolinium-based-magnetic-resonance-imaging-mri-injectable-contrast-agents-in-the-us-302247720.html
SOURCE Zydus Lifesciences Limited